

# Registry of Autoimmune Interstitial Lung Disease

NCT05365009

---

Status	RECRUITING
Sponsor	EPIMAR registry
Enrollment	1,000 participants

## Plain Language Summary

---

This registry study is collecting clinical information on people with interstitial lung disease (ILD) — scarring or inflammation of the lungs — that is associated with autoimmune conditions such as rheumatoid arthritis, lupus, or scleroderma, to better understand the disease and improve future care.

**\*\*You may be eligible if...\*\***

- You are 18 or older
- You have been diagnosed with ILD within the last 5 years by a multidisciplinary team (including a lung specialist and a rheumatologist)
- Your ILD is confirmed by a recent high-resolution CT scan showing specific patterns of lung changes
- You have an established or suspected autoimmune condition, or have been referred for evaluation of one

**\*\*You may NOT be eligible if...\*\***

- Your ILD diagnosis was more than 5 years ago
- Your lung disease is not associated with an autoimmune condition
- You are unable to provide consent

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (7)

- Age e 18 years old
  - Diagnosis of ILD within the last 5 years according to the criteria of the multidisciplinary team composed of at least one pulmonologist and one rheumatologist, with or without respiratory symptoms.
  - ILD defined by the presence of ground glass opacities and / or peribronchovascular or airspace consolidations and / or reticulations and / or traction bronchiectasis and / or honeycomb on high-resolution computed tomography (HRCT) within the last 12 months 17 .
  - One of the following three criteria (see annex 1):
  - Established or early stage CTD 18-30. IPAF according to ATS / ERS 2015 classification criteria 8 ANCA positivity by immunofluorescence confirmed by ELISA, with or without systemic vasculitis 31.
- ... and 2 more (see full listing online)

### Exclusion (3)

- Not being able to perform the clinical follow-up or the complementary studies required in the protocol.
- Not being able to be evaluated by a multidisciplinary team; at least a rheumatologist plus a pulmonologist.
- ILD associated with another non-autoimmune etiology according to the criteria of the multidisciplinary team (eg, occupational diseases, toxic)

## Locations (1 total)

---

Epimar li, Buenos Aires, Argentina

<https://clinicaltrials.gov/study/NCT05365009>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).